Phibro Animal Health Corporation
$56.51
▲
1.39%
2026-04-21 08:44:00
www.pahc.com
NGM: PAHC
Explore Phibro Animal Health Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.29 B
Current Price
$56.51
52W High / Low
$60.08 / $16.16
Stock P/E
24.91
Book Value
$8.2
Dividend Yield
0.85%
ROCE
10.35%
ROE
31.8%
Face Value
—
EPS
$2.26
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,475
Beta
0.69
Debt / Equity
233.04
Current Ratio
3.05
Quick Ratio
1.25
Forward P/E
17.21
Price / Sales
1.6
Enterprise Value
$3.05 B
EV / EBITDA
13.31
EV / Revenue
2.08
Rating
None
Target Price
$48.5
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Meaningful dividend yield is available.
Cons
- Leverage is relatively high.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zhengye Biotechnology Holding Limited | $0.95 | — | $47.54 M | 0.05% | 4.81% | -6.38% | $14.3 / $0.68 | $0.91 |
| 2. | Zoetis Inc. | $118.25 | 19.63 | $49.71 B | 1.64% | 27.18% | 65.99% | $172.23 / $113.29 | $7.84 |
| 3. | Talphera, Inc. | $0.78 | — | $40.17 M | — | -52.04% | -1.15% | $1.57 / $0.38 | $0.34 |
| 4. | Regencell Bioscience Holdings Limited | $29.09 | — | $13.89 B | — | -57.45% | -54.81% | $83.6 / $0.7 | $0.01 |
| 5. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 6. | Liquidia Corporation | $37.66 | — | $3.32 B | — | -26.74% | -1.11% | $46.67 / $11.85 | $0.51 |
| 7. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 373.91 M | 363.89 M | 378.7 M | 347.82 M | 309.26 M |
| Operating Profit | 50.33 M | 51.26 M | 33.72 M | 33.52 M | 25.53 M |
| Net Profit | 27.46 M | 26.53 M | 17.22 M | 20.88 M | 3.19 M |
| EPS in Rs | 1.33 | 1.29 | 0.84 | 1.01 | 0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.3 B | 1.02 B | 977.89 M | 942.26 M |
| Operating Profit | 110.47 M | 53.31 M | 71.85 M | 78.99 M |
| Net Profit | 48.26 M | 2.42 M | 32.61 M | 49.17 M |
| EPS in Rs | 2.34 | 0.12 | 1.58 | 2.38 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.36 B | 982.18 M | 971.4 M | 931.7 M |
| Total Liabilities | 1.08 B | 725.54 M | 688.89 M | 669.26 M |
| Equity | 285.68 M | 256.64 M | 282.51 M | 262.44 M |
| Current Assets | 810.61 M | 601 M | 585.72 M | 566.23 M |
| Current Liabilities | 293.47 M | 204.15 M | 176 M | 190.83 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 80.12 M | 87.59 M | 13.31 M | 31.65 M |
| Investing CF | -288.69 M | -48.19 M | -74.02 M | -22.58 M |
| Financing CF | 207.13 M | -6.77 M | 26.99 M | 16.34 M |
| Free CF | 41.83 M | 46.36 M | -38.48 M | -5.39 M |
| Capex | -38.29 M | -41.24 M | -51.79 M | -37.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 27.37% | 4.07% | 3.78% | — |
| Earnings Growth % | 1897.68% | -92.59% | -33.69% | — |
| Profit Margin % | 3.72% | 0.24% | 3.33% | 5.22% |
| Operating Margin % | 8.52% | 5.24% | 7.35% | 8.38% |
| Gross Margin % | 30.85% | 30.77% | 30.5% | 30.29% |
| EBITDA Margin % | 11.33% | 6.79% | 10.84% | 12.43% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-03-04 | $0.12 |
| 2025-11-26 | $0.12 |
| 2025-09-03 | $0.12 |
| 2025-06-04 | $0.12 |
| 2025-03-05 | $0.12 |
Stock Splits
No stock split history available.